US Bancorp DE lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 10.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 44,242 shares of the medical device company’s stock after purchasing an additional 4,186 shares during the quarter. US Bancorp DE’s holdings in DexCom were worth $4,203,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently made changes to their positions in DXCM. Rockefeller Capital Management L.P. bought a new stake in shares of DexCom during the 1st quarter valued at approximately $67,132,000. Point72 Asset Management L.P. grew its holdings in shares of DexCom by 429.3% during the 1st quarter. Point72 Asset Management L.P. now owns 979,175 shares of the medical device company’s stock valued at $72,616,000 after purchasing an additional 794,175 shares during the last quarter. Neuberger Berman Group LLC grew its holdings in shares of DexCom by 501.9% during the 1st quarter. Neuberger Berman Group LLC now owns 637,416 shares of the medical device company’s stock valued at $47,271,000 after purchasing an additional 531,513 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of DexCom by 67,520.1% during the 2nd quarter. Victory Capital Management Inc. now owns 494,303 shares of the medical device company’s stock valued at $46,948,000 after purchasing an additional 493,572 shares during the last quarter. Finally, Columbus Circle Investors grew its holdings in shares of DexCom by 192.3% during the 2nd quarter. Columbus Circle Investors now owns 532,489 shares of the medical device company’s stock valued at $50,576,000 after purchasing an additional 350,339 shares during the last quarter.

Several brokerages recently issued reports on DXCM. Robert W. Baird lifted their price target on shares of DexCom from $140.00 to $160.00 and gave the company a “positive” rating in a report on Thursday, August 23rd. Stephens boosted their target price on shares of DexCom from $135.00 to $160.00 and gave the stock an “overweight” rating in a report on Thursday, August 23rd. Canaccord Genuity boosted their target price on shares of DexCom from $125.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, August 23rd. BidaskClub raised shares of DexCom from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 21st. Finally, Bank of America boosted their target price on shares of DexCom from $127.00 to $145.00 and gave the stock a “buy” rating in a report on Wednesday, August 15th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have issued a buy rating and two have given a strong buy rating to the company’s stock. DexCom currently has an average rating of “Buy” and a consensus price target of $111.64.

In other news, insider Terrance H. Gregg sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, June 15th. The shares were sold at an average price of $97.81, for a total value of $978,100.00. Following the transaction, the insider now owns 501,674 shares in the company, valued at approximately $49,068,733.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Eric Topol sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 12th. The stock was sold at an average price of $100.10, for a total transaction of $2,002,000.00. Following the completion of the transaction, the director now owns 3,695 shares in the company, valued at approximately $369,869.50. The disclosure for this sale can be found here. Insiders sold a total of 198,171 shares of company stock worth $21,212,402 in the last 90 days. Corporate insiders own 1.80% of the company’s stock.

DXCM opened at $144.40 on Friday. DexCom, Inc. has a fifty-two week low of $42.62 and a fifty-two week high of $145.47. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.62 and a current ratio of 4.89. The company has a market cap of $12.51 billion, a price-to-earnings ratio of -248.97 and a beta of 0.05.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Wednesday, August 1st. The medical device company reported ($0.10) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.08. The firm had revenue of $242.50 million for the quarter, compared to the consensus estimate of $205.81 million. DexCom had a negative net margin of 0.65% and a negative return on equity of 7.45%. The company’s revenue for the quarter was up 42.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.16) EPS. equities research analysts forecast that DexCom, Inc. will post -0.48 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Further Reading: What is a Leveraged Buyout (LBO)?

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.